Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

Completed

• Conditions: Asthma
• Interventions: Combination Product: MF/IND/GLY plus sensor system; Drug: FDC therapy

• Registration Number: NCT04656223
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study is designed as a multicenter, observational, non-interventional, open label, 26-week study in order to observe how asthma control changes under treatment with Mometasone Fuorat/Indacaterol/ Glycopyrronium (MF/IND/GLY) Breezhaler® sensor system or under treatment with fixed-dose combination (FDC) triple therapy after 26 weeks of treatment.

Detailed Description

Subjects in one group will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® and access to the smartphone app according to label. Subjects in the other group will receive any triple FDC according to label. The physician's decision to initiate or switch a patient to MF/IND/GLY Breezhaler® system or any other triple FDC must have been taken prior to and independently from the decision to include the patient in the study.

Study Timeline

• Study First Submitted: 2020-11-30
• Study First Submitted QC: 2020-11-30
• Study First Posted: 2020-12-07
• Study Start: 2020-12-17
• Primary Completion: 2023-01-20
• Study Completion: 2023-01-20
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-22
• Last Update Posted: 2024-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 434

Inclusion Criteria

To participate in the study, all of the following inclusion criteria must be met:

1. Patients (m/f/d) at the age of ≥18

2. Written declaration of consent

3. Asthma diagnosis according to German Asthma Guideline NVL, 4th edition

4. Suitability for a therapy with MF/IND/GLY in combination with the sensor system or another ICS+LABA+LAMA FDC according to SPC

5. At least 6 months of inhaled therapy with ICS+LABA (high dose) or ICS+LABA+LAMA (medium or high dose) before switching or escalating asthma medication at baseline

6. Change or escalation of the asthma medication to MF/IND/GLY in combination with the sensor system or another ICS+LABA+LAMA FDC according to the therapy decision of the treating physician

7. Availability of at least one ACT value of the last 6 months before consent

8. Cohort treated with MF/IND/GLY in combination with the sensor system

   • Owning an Android or iOS smartphone or tablet on which the app can be installed (via WiFi or mobile data network) and run (requires about 75 megabytes of storage space) and which is capable of establishing a Bluetooth connection to the sensor The patient must agree to activate the app, the Bluetooth connection and the mobile data connection regularly (at least once a month).
   • Availability of an e-mail address

Read More

Exclusion Criteria

To participate in the study, none of the following exclusion criteria must apply:

1. Use of a digital inhaler-coupled inhalation tracking system to support adherence in the last 3 months prior to study entry
2. Simultaneous participation in an interventional study or in another Novartis-sponsored noninterventional study
3. Asthma therapy with a biological agent, if not stable at the same dosage for at least 3 months

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
MF/IND/GLY Breezhaler® plus Propeller Health	MF/IND/GLY plus sensor system	patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
Other FDC therapy	FDC therapy	patients receiving ICS+LABA+LAMA FDC therapy according to label

Primary Outcome Measures

Name	Time	Method
Change in asthma control test (ACT) score	Baseline, week 26	ACT assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control.; It is a self-administered questionnaire comprising five items that are assessed on a five point categorical scale (1 to 5) and the scores are summed to give a total score ranging from 5 to 25, with a score of \>=20 denoting 'controlled asthma', a score of 16-19 denoting 'partially controlled asthma', and a score of \<=15 denoting 'uncontrolled asthma'. The total score is calculated as the sum of the scores from all 5 questions. Higher scores indicates improved asthma control.

Secondary Outcome Measures

Name	Time	Method
Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician	Baseline	Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician will be provided
Percentage of patients showing an improvement in self-reported test adherence to inhalers (TAI) questionnaire	26 weeks	TAI test is a 12-item questionnaire designed to assess the adherence to inhalers in patients with asthma.; Ten questions are answered by the patients, and have to rate each question from 1 to 5. Total score can go between 10 and 50; 50 points correlates to "adherent", 46-49 points correlates to "moderate adherent" and lower than 45 points correlate to "not adherent".; Two additional questions are answered by the physician
Percentage of patients achieving the minimal clinically important difference (MCID) change	Baseline, week 26	Percentage of patients achieving the minimal clinically important difference (MCID) change from baseline ACT ≥ 3 points will be provided
Percentage of patients with an ACT score <19	26 weeks	Percentage of patients with an ACT score of \<19 at baseline and following 26 weeks will be provided
Course of adherence in the subgroup receiving MF/IND/GLY plus sensor	26 weeks	Adherence course according to inhalation tracking data in the subgroup treated with MF/IND/GLY plus sensor will be provided
Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor	26 weeks	Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor will be provided
Description of of patient characteristics at baseline	Baseline	Description of patient characteristics at baseline in the treatment groups receiving MF/IND/GLY plus sensor or triple FDC will be provided
Change in Post-dose trough Forced Expiratory Volume in one second (FEV1)	Baseline, week 26	FEV 1 it is the amount that is exhaled in the first second of purposefully trying to breathe out as much air as possible.
Change in Forced vital capacity (FVC)	Baseline, week 26	FVC is the volume of air that can forcibly be blown out after full inspiration, measured in liters.
Adverse events	26 weeks	Adverse events will be provided

Trial Locations

Locations (1)

Novartis Investigative Site; 🇩🇪 Wiesbaden, Germany